Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
Massaro F, Stepanishyna Y, Manni M, Luminari S, Galimberti S, Marcheselli L, Visco C, Tecchio C, Stelitano C, Angrilli F, Petrini M, Merli F, Federico M. Massaro F, et al. Among authors: stepanishyna y. Br J Haematol. 2021 Mar;192(6):1011-1014. doi: 10.1111/bjh.16714. Epub 2020 May 14. Br J Haematol. 2021. PMID: 32410259 Free article. Clinical Trial.
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.
Alonso-Álvarez S, Manni M, Montoto S, Sarkozy C, Morschhauser F, Wondergem MJ, Guarini A, Magnano L, Alcoceba M, Chamuleau M, Galimberti S, Gomes da Silva M, Holte H, Zucca E, Lockmer S, Aurer I, Marcheselli L, Stepanishyna Y, Caballero Barrigón MD, Salles G, Federico M. Alonso-Álvarez S, et al. Among authors: stepanishyna y. Eur J Cancer. 2021 Nov;157:132-139. doi: 10.1016/j.ejca.2021.08.005. Epub 2021 Sep 8. Eur J Cancer. 2021. PMID: 34508995
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project.
Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NPC, Pileri SA, Montoto S, Horwitz SM, Cabrera ME, De Souza CA, Nagler A, Luminari S, Ferreri AJM, Carson KR, Re A, Rigacci L, Nassi L, Stepanishyna Y, Federico M, Inghirami G. Chiattone C, et al. Among authors: stepanishyna y. Hematol Oncol. 2022 Dec;40(5):953-961. doi: 10.1002/hon.3074. Epub 2022 Sep 15. Hematol Oncol. 2022. PMID: 36083035
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
Hapgood G, Civallero M, Stepanishyna Y, Vose J, Cabrera ME, Advani RH, Pileri SA, Manni M, Horwitz SM, Foss FM, Hitz F, Radford J, Dlouhy I, Chiattone C, Kim WS, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M. Hapgood G, et al. Among authors: stepanishyna y. Blood Adv. 2023 Sep 12;7(17):5047-5054. doi: 10.1182/bloodadvances.2023010037. Blood Adv. 2023. PMID: 37163360 Free PMC article.
Reply to T. Vassilakopoulos et al.
Federico M, Plattel W, Hutchings M, Stepanishyna Y, Fortpied C, André M. Federico M, et al. Among authors: stepanishyna y. J Clin Oncol. 2024 Apr 9:JCO2400143. doi: 10.1200/JCO.24.00143. Online ahead of print. J Clin Oncol. 2024. PMID: 38593392 No abstract available.
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
Civallero M, Schroers-Martin JG, Horwitz S, Manni M, Stepanishyna Y, Cabrera ME, Vose J, Spina M, Hitz F, Nagler A, Montoto S, Chiattone C, Skrypets T, Perez Saenz MA, Priolo G, Luminari S, Lymboussaki A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D, Federico M, Advani R. Civallero M, et al. Among authors: stepanishyna y. Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19433. Online ahead of print. Br J Haematol. 2024. PMID: 38532575
Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
Stepanishyna Y, Manni M, Civallero M, Shokun N, Skrypets T, Burtna A, Shapovalenko N, Tytorenko I, Aleksyk O, Pastushenko Y, Gubareva H, Moiseienko K, Kadnikova T, Rudyuk T, Filonenko K, Martynchyk A, Novosad O, Galli GR, Kryachok I, Federico M. Stepanishyna Y, et al. Br J Haematol. 2024 May;204(5):1757-1761. doi: 10.1111/bjh.19352. Epub 2024 Feb 23. Br J Haematol. 2024. PMID: 38400556
NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
Kriachok I, Tytorenko I, Shudrak N, Aleksik O, Stepanishyna Y, Kadnikova T, Pastushenko Y, Shokun N, Rudiyk T, Bushuieva M. Kriachok I, et al. Among authors: stepanishyna y. Exp Oncol. 2024 Feb 3;45(4):474-482. doi: 10.15407/exp-oncology.2023.04.474. Exp Oncol. 2024. PMID: 38328842
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, Re A, Plattel W, Lazarovici J, Merli F, Specht L, Schiano de Colella JM, Hutchings M, Versari A, Edeline V, Stamatoulas A, Girinsky T, Ricardi U, Aleman B, Meulemans B, Tonino S, Raemaekers J, André M. Federico M, et al. Among authors: stepanishyna y. J Clin Oncol. 2024 Jan 1;42(1):19-25. doi: 10.1200/JCO.23.01745. Epub 2023 Nov 15. J Clin Oncol. 2024. PMID: 37967311 Clinical Trial.
13 results